Galenica (GALE) Q1 2026 TU earnings summary

Executive summary

• Net sales increased by 7.3% year-over-year to CHF 1,409.7 million, driven by acquisitions, pharmacy, and wholesale business expansion.

• Home care and diagnostics segments contributed positively, with diagnostics adding CHF 40.8 million after the Labor Team acquisition.

• Diversified business model helped offset seasonal declines in cold and pain relief product sales.

• Both Products & Care and Logistics & IT segments contributed to overall sales growth.

Financial highlights

• Products & Care segment sales rose 11.6% to CHF 637.7 million compared to the same period last year.

• Logistics & IT segment sales grew 4.3% to CHF 1,110.2 million year-over-year.

• Pharmacies Omni-Channel sales up 6.9% to CHF 495.5 million, supported by prescription medicines and acquisitions.

• Services & Production sales increased 9.1% to CHF 41.9 million, led by homecare services.

• Wholesale sales up 4.4% to CHF 1,085.1 million, with further market share gains in pharmacy segments.

Outlook and guidance

• Sales growth for 2026 expected between 5% and 7%; EBIT growth forecasted at 6% to 8%.

• Continued growth expected, supported by recent acquisitions and expansion in pharmacy locations.

• Dividend anticipated to be at least at the previous year's level.

• Market conditions remain favorable, with the Swiss pharmaceutical market growing 4.1% year-over-year.